Introduction {#Sec1}
============

In December 2019, several cases of unexplained pneumonia appeared in Wuhan, China. In January 2020, the cause for such diseases was identified in a new enveloped RNA coronavirus detected in samples of bronchoalveolar lavage fluid from a Chinese patient \[[@CR1]\]. Afterwards, further studies showed a close similarity with the virus responsible for SARS infection in 2003; hence, it was named SARS-CoV-2 \[[@CR2]\]. One month later, the illness associated with such virus was termed COVID-19. Due to the rapid and extensive spreading of the infection from China to Europe and worldwide, the WHO declared COVID-19 a public health emergency of international concern (PHEIC) \[[@CR3]\], expressing the urge for a strong response from global public health. Up to date (June 7, 2020), more than 6.6 million confirmed cases of COVID-19 have been diagnosed worldwide, with 392.802 deaths \[[@CR4]\].

Despite world updates produced daily, general knowledge of COVID-19 remains unclear. COVID-19 is mainly considered primarily a respiratory disease and so much of the guidance and papers focus on such physical manifestations and their management. Nevertheless, there is a possible viral transmission to the nervous system that may occur via circulation, an upper transcribrial or conjunctival route \[[@CR5], [@CR6]\]. In the broad sweep of available data, neurological and psychiatric evidence on SARS-CoV-2 are limited. Reliable and up-to-date answers to immediate clinical questions can be difficult and time-consuming particularly regarding treatment strategies \[[@CR7], [@CR8]\].

We herein reviewed the best evidence on SARS-CoV-2 and neurological disorders simultaneously with COVID-19 neurological and psychiatric sequelae, including the paediatric population. Indeed, children affected by neurological disorders could be particularly vulnerable in the context of COVID-19, both directly because of their physical difficulties, but also because of the challenging issue of treatment needs alongside drug's long-term effects. These factors together with the adverse psychological effects of measures, such as self-isolation and disruption to normal healthcare and lifestyle, make this population worthy of attention \[[@CR9], [@CR10]\].

Search strategy {#Sec2}
===============

We performed a systematic search on PubMed using the terms "COVID 19" OR "coronavirus" AND "brain" OR "CNS" OR "neurologic "OR "psychiatric". We included case reports and clinical trials. Searches cover the period up to June 6, 2020. Only studies published in English were reviewed.

CNS invasion by SARS-CoV-2 {#Sec3}
==========================

Human coronaviruses (HCoVs) commonly share viral structures and infection mechanisms, together with the potential for host central nervous system (CNS) invasion \[[@CR11], [@CR12]\]. The exact route by which HCoVs enter the CNS remains a topic of active investigation. Tissue distribution of host receptor angiotensin-converting enzyme 2 (ACE2) may not be solely sufficient to fully describe viral tropism \[[@CR11], [@CR13]\] and other mechanisms (such as axonal transport) are likely to be involved \[[@CR14], [@CR15]\].

Aerosol droplets allow HCoVs to firstly locate in the nasal mucosa of the infected host, subsequently gaining access to the CNS through a transcribrial route \[[@CR11], [@CR14], [@CR16]\]. Concurrently, viremia disseminates HCoV through the bloodstream, which is an additional route to reach the cerebral blood flow \[[@CR17]\]. Once in the CNS, the membrane-bound ACE2 receptor, which is ubiquitous and detectable also over the cerebral capillary endothelium, glial cells, and neurons, assures CoVs to fuse with cells' surface via spike proteins \[[@CR17]\]. To prove this, mice transgenic (Tg) for human ACE2 resulted as highly susceptible to CoV inoculation, with broad brain invasion and death within a few days \[[@CR15]\]. Once strong adhesion is guaranteed, an additional axonal transport leads to early infection spread to the piriform cortex and other regions associated with olfaction \[[@CR14]\]. Within a few days after infection, HCoVs widely diffuse to the CNS, being detectable in the brains of infected mice or healthy patients time after the acute manifestations of the disease \[[@CR11], [@CR14]\]. Similar mechanisms of neuron-to-neuron HCoV transport might potentially involve all sensory nerves, depending on the entering site (e.g. nasopharyngeal or oropharyngeal). Therefore, the sensory branches of the trigeminal and vagal nerves may also lead to viral invasion of the brainstem nuclei, and later to the cerebrum and cerebellum \[[@CR11], [@CR14], [@CR16]\].

HCoVs share high similarities and common neurotropic features, and there is no evidence that SARS-CoV-2 may not be an exception \[[@CR11], [@CR18], [@CR19]\]. First description of patients with meningitis or encephalitis whose cerebrospinal fluid (CSF) tested positive for SARS-CoV-2 by gene sequencing is described. Moreover, other neurological manifestations such as headache, impaired consciousness, psychiatric symptoms, and acute cerebrovascular diseases have been reported in patients with COVID-19 \[[@CR12], [@CR20]--[@CR22]\]. The mechanism provided for cerebrovascular diseases, however, is probably different and does not require a direct viral invasion of the CNS. It seems that COVID-19 can cause a cytokine storm syndrome which, together with the elevation of D-dimer levels, platelet reduction, and hypoxia, may cause susceptibility to cerebrovascular events \[[@CR15], [@CR23], [@CR24]\]. On the other hand, the systemic dysregulation of homeostasis in the infected host can influence the CNS, too. However, infected glial cells and neurons may also play a significant role in CNS tissue damage, having in vitro properties to secrete inflammatory cytokines and so potentially perpetuating inflammation and causing demyelination, oedema, and long-term neurological sequelae \[[@CR15], [@CR17], [@CR18], [@CR24]\]. Moreover, the direct infection of cardiorespiratory centres in the CNS seems strong to contribute to respiratory failure and death in SARS-CoV-2-affected patients \[[@CR11], [@CR15], [@CR18]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mechanisms of SARS-CoV-2 CNS invasion or damage and related symptoms. CNS = central nervous system; BBB = blood-brain barrier

Neurological symptoms associated with SARS-CoV-2 {#Sec4}
================================================

Similarly to other coronaviruses, SARS-CoV-2 could be associated with neurological complications. Such involvement has been observed in more severe cases and could be directly triggered by the virus itself or by the systemic consequences of the infection. Particularly, during elderly and in people with cardiac or endocrinological comorbidities, COVID-19 could manifest with fewer typical symptoms (namely flu-like symptoms), giving otherwise rise to more severe neurological manifestations. Hence, COVID-19 has to be suspected in the differential diagnosis of patients with neurological symptoms, especially in highly epidemic environments \[[@CR11], [@CR22], [@CR25]\].

In the large study by Mao et al., 78 out of the 214 (36.4%) patients did show neurological manifestations. Among these, the most common were dizziness and headache, whereas the peripheral nervous system (PNS) manifestations mainly included alterations in smell and taste (up to 5.6 and 5.1% of patients, respectively) \[[@CR22]\]. Hitherto, the prevalence of COVID-19-related olfactory and taste disorders (OTDs) has been investigated through questionnaires and interviews \[[@CR26], [@CR27]\]. Results showed higher rates of OTDs in Europe compared with Asia and highlighted that olfactory disorders (both hyposmia and anosmia) are likely to appear even before other much-known symptoms of the COVID-19 \[[@CR26]\]. Given that the olfactory and sensory nerves are supposed to be the first route to CNS invasion, and that it may precede the viral spread to other related cerebral regions \[[@CR14]\], anosmia constitutes an interesting and early neurological manifestation of SARS-CoV-2 that may help for the timely suspicion and isolation of COVID-19 patients.

One of the first cases of COVID-19 with positive neurological signs was reported by Yin et al. \[[@CR20]\], who described a patient with severe cognitive impairment, bilateral ankle clonus, positive Babinski, and meningeal signs. However, head CT scan was unremarkable and viral genome was not detected in the CSF. Nonetheless, similar findings have been reported as well in other patients \[[@CR28], [@CR29]\] whose cerebral spinal fluid tested positive for SARS-CoV-2 RNA, suggesting COVID-19-related encephalitis. In one patient, brain MRI showed a signal hyperintensity in the medial temporal lobe on T2 and fluid-attenuated inversion recovery (FLAIR) sequences, consistent with the hypothesis of ongoing acute encephalitis. Furthermore, shreds of evidence have shown that SARS-CoV-2 can elicit a cytokine storm, which in turn might be associated with severe organ damage, including the CNS. Poyiadji et al. \[[@CR30]\] reported a patient with acute haemorrhagic necrotizing encephalopathy, a rare complication of specific viral infections \[[@CR31]\] which has been linked to intracranial cytokine storms. In this patient, brain CT and MRI detected inflammatory lesions involving the medial temporal lobes along with the thalami and the insular regions. Moreover, we should consider that cytokine storms have been linked to the onset of multiple organ failure \[[@CR32]\]; hence, they could also indirectly affect the nervous system.

Like other viruses and bacteria, it seems that SARS-CoV-2 as well could trigger acute cerebrovascular diseases (CVD), such as ischemic or haemorrhagic stroke and cerebral venous sinus thrombosis, which have been reported in several patients \[[@CR22], [@CR33], [@CR34]\]. Stroke incidence was reported between 2.5 and 6% in retrospective European and Chinese studies \[[@CR22], [@CR35]\]. Such complications seem to be caused by alterations in the homeostasis of coagulation. It is noteworthy that patients with severe forms of COVID-19 showed higher levels of D-dimer \[[@CR22]\] and more serious thrombocytopenia \[[@CR36]\]. Nonetheless, numerous pieces of evidence have recognized the role of the inflammatory response as a contributor to the pathophysiology of cerebrovascular diseases \[[@CR37]\]. Consistently with this evidence, higher concentrations of C-reactive protein have been reported in patients who developed CVD \[[@CR33]\]. Recently, Li and colleagues \[[@CR11], [@CR19]\] further speculated that the involvement of the nervous system by SARS-CoV-2 may also play a role in the onset of respiratory failure occurring in COVID-19. ACE2 is expressed in the brainstem and the CNS replication of SARS-CoV-2 might directly involve the cardiorespiratory centre \[[@CR15], [@CR38]\]. Additionally, the skeletal muscle injuries that have been documented in COVID-19 patients \[[@CR22]\] might concur to the development of respiratory failure. Moreover, it is well known that severe hypoxia, which often presents in patients with COVID-19, can lead to brain damage with cerebral vasodilation and interstitial oedema. These effects might indeed be precipitated or worsened by an overlapping respiratory failure.

Finally, several authors reported cases of Guillain-Barré syndrome associated with SARS-CoV-2 infection \[[@CR39]--[@CR42]\]. The main etiopathological hypothesis involves "molecular mimicry", by which specific viral antigens and myelin or axonal epitopes may lead to cross-reactive of immune responses and inflammatory damage of the peripheral nerve fibres. Toscano and colleagues \[[@CR40]\] described five patients who developed GBS 5--7 days after the onset of COVID-19 symptoms: Three of them presented an axonal variant, whereas two had a demyelinating form. Interestingly, CSF was negative for SARS-CoV-2 RNA in all cases, and anti-ganglioside antibodies were not detected in the three patients who were tested. A similar case was reported by Camdessanche et al. who described a 64-year-old man with a demyelinating form of GBS whose CSF is negative for anti-ganglioside antibodies \[[@CR43]\].

Impact of COVID-19 in patients with chronic neurological diseases {#Sec5}
=================================================================

SARS-CoV-2 infection has impacted on the health and well-being of patients with chronic neurological diseases. In fact, despite the lack of published evidence, it seems reasonable to presume that patients with chronic neurological disorders may both be at increased risk of contracting the virus (i.e. for primary or acquired immune deficiencies, higher risk of hospitalization and daily living in institutions) and of experiencing a more severe infection. Nonetheless, SARS-CoV-2, like other pathogens, may re-exacerbate or worsen previously diagnosed neurological diseases. For these reasons, many national and international scientific societies and disease foundations dealing with neurological disorders have acted to adequately inform, prevent and treat these patients \[[@CR44]\]. Patients treated with biological drugs and immunosuppressive therapy (IST) are more vulnerable to all kinds of infections. Brownlee et al. \[[@CR45]\] reviewed the indications for the management of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) during COVID-19 pandemic. While enlightening the general lack of evidence about the risks of IST in milder forms of COVID-19, they recommended that clinicians should consider interrupting treatment in case of comorbidities or worsening of symptoms. However, there are contradictory opinions on this issue, since other authors suggest that the moderate immunosuppression induced by MS treatments may protect from developing more severe forms of COVID-19 \[[@CR46]\]. In addition to this, authors expressed their doubts about the short-term usage of high-dose corticosteroids in MS relapses during the pandemic, since it does not influence the final degree of recovery and could be associated with a higher risk of viral reactivation \[[@CR47]\]; therefore, they advised to keep a high threshold on the administration of such treatment. In patients requiring a high-efficiency therapy for MS during this period, natalizumab might be a better choice compared with other treatments that could lead to complications, such as transient lymphopenia, or increase hospital accesses for monitoring drug levels. No special advice so far has concerned children with MS \[[@CR44]\].

Patients affected by neuromuscular diseases (NMD) should also be considered a population at more prone to COVID-19 complications \[[@CR48]\]. Some of them may be at higher risk for infection, such as those with the involvement of swallowing and breathing muscles, with other comorbidities or under IST (such as steroids). Furthermore, infections can be a trigger for disease exacerbation or progression in NMD, like in myasthenia gravis \[[@CR49]\] or spinal muscular atrophy, and patients with NMD and acute respiratory illnesses present a much higher risk of respiratory failure and need for intensive care. Hence, clinicians should consider that COVID-19 might not represent an exception to this evidence, and therefore worsen clinical conditions of patients with NMD or unmask previously undiagnosed pathologies. There are no current indications for interrupting or changing an ongoing therapy, even with immunosuppressant drugs \[[@CR48]\]; however, careful surveillance of these patients should be advisable. Finally, a global pandemic is certainly a stressful event that can affect both physical and mental health, quality of sleep and daily routines. In this sense, patients with migraine or other headache disorders may be more prone to be affected by those stressors and experience more severe or more frequent headache episodes.

So far, most drugs used in paediatric patients seem to have no contraindications in COVID-19 \[[@CR50]\]. Some initial doubts regarding the safety of NSAIDs (e.g. ibuprofen) have been rejected by the WHO and EMA \[[@CR51]\] due to the lack of evidence on the association of their administration with a worse outcome of COVID-19. Nonetheless, recommendations may eventually change according to our better understanding of the disease. Evidence on these and other categories of patients are still to be obtained. Hence, a constant update of clinicians is required. Finally, due to the need of carefully monitoring their patients, child neurology specialists should consider that a helpful tool might be represented by telemedicine, which has been proven to obtain similar satisfaction rates and eventual outcomes compared with traditional visit for different diseases \[[@CR52]--[@CR54]\].

Neurological complications of COVID-19-related treatments {#Sec6}
=========================================================

As treatment for COVID-19 constantly evolves, following the newest evidence of efficacy and clinical trials, neurologists should be aware and constantly updated on the main nervous system side effects of these therapies. Besides supportive treatments, the drugs that are mainly used both for children and adults are anti-inflammatory and antiviral agents, eventually in association with anti-thrombotic therapy \[[@CR55]\].

The main interactions between antiviral therapies and neurologic and psychiatric drugs are reported in Table [1](#Tab1){ref-type="table"}. Among these, chloroquine and hydroxychloroquine have been administered in COVID-19 even in milder forms \[[@CR56], [@CR57]\], although the use of both drugs has recently shown contradictory results \[[@CR58]--[@CR60]\]. In particular, a small Chinese randomized trial reported no differences in virologic outcomes \[[@CR59]\], and the Survival Sepsis Campaign guidelines on the management of critically ill adults with COVID-19 stated that there was insufficient evidence for recommending the use of hydroxychloroquine and chloroquine in this group of patients. Different organizations, including the Italian Medicines Agency (AIFA), have suspended the employment of hydroxychloroquine outside clinical trials \[[@CR61]\]. Seizures have been observed in the past in some patients treated with chloroquine \[[@CR62]\]. Moreover, due to their association with QT prolongation, co-administration with drugs eliciting the same side effect (e.g. tricyclic antidepressants) is discouraged and should be carefully used in patients with cardiac diseases (e.g. NMD-related heart failure). Furthermore according to Russo et al., chloroquine and hydroxychloroquine, as well as Remdesivir, an antiviral agent used in COVID-19 \[[@CR63], [@CR64]\], should not be co-administered with carbamazepine, phenytoin, phenobarbital and primidone, for the risk of drug interactions and enzymatic induction of inhibition \[[@CR65]\]. Lopinavir and ritonavir have been employed in COVID-19 treatment \[[@CR66]\], although contradictory results have been observed and their effectiveness is still debatable \[[@CR67]\]. Moreover, ritonavir may promote the metabolism of phenytoin and other antiepileptic and antipsychotic drugs due to the induction of CYP450 \[[@CR68]\]. Furthermore, azithromycin has proven efficacy in COVID-19 in association with hydroxychloroquine \[[@CR57]\]. Nonetheless, patients with myasthenia gravis taking macrolides should be monitored, as they have been reported to exacerbate symptoms or trigger a new-onset myasthenic syndrome \[[@CR69]\]. Finally, the monoclonal antibodies employed in COVID-19 trials (mainly tocilizumab \[[@CR66]\] and anakinra \[[@CR70]\]) have not shown nervous system side effects or interactions with neurological diseases.Table 1SARS-CoV-2 drugs interactions with co-medications*DRV/c* darunavir/cobicistat; *LPV/r* lopinavir/ritonavir; *RDV* remdesivir; *FAVI* favipiravir; *CLQ* chloroquine; *HCLQ* hydroxychloroquine; *NITA* nitazoxanide; *RBV* ribavirin; *OSV* oseltamivir; *LTG* lamotrigine; *CBZ* carbamazepine; *VPA* valproic acid; *QTc* corrected QT interval; *NA* not available, very low evidences; *BDZs* benzodiazepines; *DZP* diazepam; *CZP* clonazepam; *MDZ* midazolam; *ALP* alprazolam; *PHB* phenobarbital; *PD* primidone; *AMT* amitriptyline; *BP* bupropion; *CTL* citalopram; *CLP* clomipramine; *ESC* escitalopram; *MRT* mirtazapine; *PRX* paroxetine; *SRT* sertraline; *TRZ* trazodone; *VLX* venlafaxine; *AEDs* anti-epileptic drugs; *CBD* cannabidiol; *ETX* ethosuximide; *FBM* felbamate; *PER* perampanel; *HLP* haloperidol; *CPZ* chlorpromazine; *RSP* risperidone; *OLP* olanzapine

Neurological involvement in children {#Sec7}
====================================

COVID-19 seems to have a relatively low prevalence in children, which represent from 1.7 \[[@CR71]\] to 2.4% \[[@CR72]\] of patients. In Italy, 1.9% of reported cases were \< 19 years old \[[@CR73]\]. Nonetheless, SARS-CoV-2 infection shows different characteristics in children compared with the adult population, such as a longer incubation period (6**.**5 vs. 5.4 days \[[@CR74]\]), a milder course and a reduced fatality \[[@CR5]\]. Furthermore, typical symptoms of COVID-19 like fever, cough and shortness of breath have been reported less frequently in children \[[@CR5], [@CR10]\]. Focusing on the neurological features, headache has been reported in up to 28% of the cases \[[@CR71]\], being the principal neurological symptom, followed by confusion, in this age group \[[@CR75]\].

Data on laboratory findings have been only occasionally described. However, Henry et al. \[[@CR76]\] collected the findings from 12 studies reporting on 66 children. According to the authors, leukocytes were normal in the vast majority of patients (69.2%), whereas factors related to abnormal coagulation, such as thrombocytopenia and increased D-dimer, are anecdotal. Moreover, C-reactive protein and procalcitonin were increased by 13.6% and 10.6% of the cases. Accordingly, it is reasonable to suspect that children have a lower risk of presenting SARS-CoV-2 neurological complications compared with adults.

Despite the milder expression of COVID-19 in the paediatric population, severe forms of the disease seem to occur mainly in younger children, with a prevalence of 10.6% and 7.3% for the age groups of \< 1 and 1--5 years, compared with 4.2%, 4.1% and 3.0% for the age groups of 6--10, 11--15 and \> 15 years \[[@CR5]\]. Although neurological complications in COVID-19 paediatric patients are a seldom finding, probably because of the milder forms of the disease, some cases have been reported. Sun et al. described a 10-month-old child who presented intussusception, multi-organ dysfunction syndrome, toxic encephalopathy, status epilepticus and disseminated intravascular coagulation \[[@CR77]\]. Furthermore, seizures have been described in a 2-year-old girl in China, who did not develop other complications and was discharged after 2 weeks of hospitalization \[[@CR78]\]. Finally, one case of encephalitis has been reported in a paediatric patient from Germany \[[@CR79]\].

Psychological burden and associated psychiatric disorders {#Sec8}
=========================================================

It is difficult to discern whether the high prevalence of psychiatric disorders diagnosed during the past SARS-CoV-1 epidemic and largely found in patients with SARS-CoV-2 infection are a direct consequence of the central nervous system involvement or are a fallout of the adverse psychological effects of unprecedented social and health measures such as quarantine, self-isolation and disruption of personal and social healthcare and lifestyle \[[@CR80]\]. SARS-CoV-2 infection has recently been implicated in the onset of psychosis, mood disorders, post-traumatic stress disorders and suicide \[[@CR81]--[@CR83]\].

Previous literature on post-traumatic stress disorders reported that more than 40% of SARS survivors had experienced post-traumatic stress symptoms at one time during the outbreak. Meanwhile, those respondents who had been isolated worked in high-risk workplaces such as SARS wards or had friends or close relatives who contacted SARS were two to three times more likely to develop high levels of post-traumatic stress symptoms than those who were not exposed to the virus. \[[@CR84]\]. Recent findings based on the actual outbreak indicate that feeling extreme fear is the most significant predictor for both depression and post-traumatic stress disorder, followed by short sleep duration and living in the worst-hit areas \[[@CR85]\].

During and following the COVID-19 outbreak, we might see an increase in suicide ideation and behaviour among at-risk populations. According to the WHO, each suicide in a population is accompanied by more than 20 suicide attempts and a recent model based on global public data from 63 countries predicted a 20--30% increase of suicide rates due to the COVID-19 pandemic \[[@CR86], [@CR87]\].

Besides the social strain, however, it is well known that viral infections may be associated with psychiatric symptoms as a direct neurotropic effect, or (most often) due to activation of a powerful immune-inflammatory response \[[@CR8]\]. There is a link between mood disorders and inflammatory cytokine levels, including tumour necrosis factor-alpha (TNF alpha), interleukins (IL-1, IL-6) and others. According to this theory, the proinflammatory cytokines responsible for the acute phase response act on the brain to induce depression. One key player in this action of cytokines in the brain is an enzyme known as indoleamine 2,3 dioxygenase (IDO) that degrades tryptophan, an essential amino acid that is the limiting factor for the synthesis of serotonin. An elevation in IDO activity is associated with alterations in brain serotonin neurotransmission and with the development of depressive-like behaviour \[[@CR76]\].

Patients with mental health disorders may be particularly vulnerable in the context of the COVID-19 pandemic, not only for their intrinsic psychiatric condition but also because of some of the long-term effects of psychotropic medication (such as metabolic syndrome with long-term antipsychotics), comorbid physical health problems and smoking habits \[[@CR7]\]. Furthermore, psychiatric treatment in COVID-19 patients is a source of medical concern. Indeed, from one side, many psychiatric patients have been infected with COVID-19, and on the other side, a contingent number of patients hospitalized for COVID-19 or simply infected by SARS-CoV-2 are experiencing psychiatric symptoms like anxiety, fear, depression and insomnia, which can be difficult to discern from antiviral treatment side effects. In this regard, many patients will need psychiatric medications including antipsychotics, antidepressants and antianxiety drugs, while using specific drugs against COVID-19, such as antiviral or anti-inflammatory. Consistently, the arising question is which drug to use to have the least possible interactions. The best choice seems to be on drugs that do not act on the cytochrome P450 or on drugs that act little on the cytochrome P450, such as citalopram, escitalopram, olanzapine and valproate, to avoid interactions with antivirals, which are metabolized via cytochrome P3A4 and cytochrome P2D6.

Other complications derived from long-lasting in ICU, like impaired consciousness ranging from somnolence to confusion, delirium, stupor and coma, have been reported in almost 15% of hospitalized patients with COVID-19 \[[@CR88]\]. Acute brain dysfunction, symptomatically presenting as delirium (also called encephalopathy), can be a feature of the neuro-invasive potential of SARS-CoV-2. The neurotropism of Coronaviridae has already been demonstrated during the SARS and MERS epidemics. In patients with COVID-19, delirium may be a manifestation of direct central nervous system (CNS) invasion, induction of CNS inflammatory mediators, a secondary effect of other organ system failure, an effect of sedative strategies, prolonged mechanical ventilation or environmental factors including social isolation. Regarding pharmacological interventions, no drugs can be recommended for the prevention or treatment of ICU delirium other than avoidance of overuse of potent psychoactive agents like sedatives and neuromuscular blockers (NMB), unless patients require such management \[[@CR86]\].

Therefore, these conditions must be identified and treated early to prevent prolonged mechanical ventilation, longer ICU and hospital length of stay, higher mortality and long-term cognitive impairment.

Conclusions {#Sec9}
===========

The coronavirus disease of 2019 (COVID-19) that is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been designated a pandemic by the World Health Organization, affecting 4.4 million individuals globally as of May 16, 2020, with over 301.059 deaths. A growing body of evidence supports CNS involvement. The clinical manifestations range from vague non-focal complaints to severe neurologic impairment associated with encephalitis. It is unclear whether neurological dysfunction is due to direct viral injury or systemic disease. The virus may affect brainstem pathways that lead to indirect respiratory dysfunction in addition to direct pulmonary injury. Necessary adaptations in management, triage and diagnosis are needed, especially for subjects suffering from chronic and disabling illness. Finally, precise and targeted documentation of neurological symptoms, detailed clinical, neurological and electrophysiological investigations of the patients, attempts to isolate SARS-CoV-2 from cerebrospinal fluid, and autopsies of the COVID-19 victims may clarify the role played by this virus in causing neurological manifestations.
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